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Background: Fibroblast growth factor 23 (FGF23) is the earliest marker of disturbed mineral metabolism as renal
function decreases. Its serum levels are associated with mortality in dialysis patients, persons with chronic kidney
disease (CKD) and prevalent cardiovascular disease (CVD), and it is associated with atherosclerosis, endothelial
dysfunction and left ventricular hypertrophy in the general population. The primary aim of this study is to examine
the association between FGF23 and mortality, in relation to renal function in the community. A secondary aim is to
examine the association between FGF23 and CVD related death.
Methods: The population-based cohort of MrOS Sweden included 3014 men (age 69–81 years). At inclusion intact
FGF23, intact parathyroid hormone (PTH), 25 hydroxyl vitamin D (25D), calcium and phosphate were measured.
Mortality data were collected after an average of 4.5 years follow-up. 352 deaths occurred, 132 of CVD. Association
between FGF23 and mortality was analyzed in quartiles of FGF23. Kaplan-Meier curves and Log-rank test were used
to examine time to events. Cox proportional hazards regression was used to examine the association between
FGF23, in quartiles and as a continuous variable, with mortality. The associations were also analyzed in the
sub-cohort with estimated glomerular filtration rate (eGFR) above 60 ml/min/1.73 m2.
Results: There was no association between FGF23 and all-cause mortality, Hazard ratio (HR) 95% confidence
interval (CI): 1.02 (0.89-1.17). For CVD death the HR (95% CI) was 1.26 (0.99 - 1.59)/(1-SD) increase in log(10)FGF23
after adjustment for eGFR, and other confounders. In the sub-cohort with eGFR > 60 ml/min/1.73 m2 the HR
(95% CI) for CVD death was 55% (13–111)/(1-SD) increase in log(10)FGF23.
Conclusions: FGF23 is not associated with mortality of all-cause in elderly community living men, but there is a
weak association with CVD death, even after adjustment for eGFR and the other confounders. The association with
CVD death is noticeable only in the sub-cohort with preserved renal function.
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Decreased renal function, defined as estimated glomerular
filtration rate (eGFR) below 60 ml/min/1.73 m2, is an inde-
pendent risk factor for mortality of cardiovascular disease
(CVD), not fully explained by traditional risk factors.
Serum concentration of fibroblast growth factor 23
(FGF23) increases in parallel with parathyroid hormone
(PTH) as renal function declines in chronic kidney disease
(CKD) to maintain phosphate and calcium homeostasis* Correspondence: per-anton.westerberg@medsci.uu.se
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distribution, and reproduction in any medium[1,2]. In an elderly population mild to moderate renal dys-
function is common and implies an increased risk for CVD
related mortality [3]. Hyperphosphatemia, increased PTH
and FGF23 have been associated with CVD risk in obser-
vational studies [4-6]. Also higher phosphate levels in the
normal range is associated with increased risk for CVD
death in individuals with prevalent coronary disease [4].
FGF23 may be a better indicator of phosphate expos-
ure, and CVD risk, in subjects with mild to moderate
renal dysfunction due to that hyperphosphatemia does
not develop until advanced renal dysfunction, serum
phosphate is subject to circadian variation and may vary
with intake, glucose metabolism and anabolic status.ntral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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trophy [7,8], extent of atherosclerosis [9], endothelial dys-
function [10], and increased risk for mortality in CKD [6]
and in those with prevalent coronary disease [11].
Serum concentration of 25 hydroxyl vitamin D (25D),
which is the precursor of active vitamin D, 1,25
dihydroxy vitamin D (1,25D), reflects the vitamin D sta-
tus of the individual. The 1,25D level is precisely regu-
lated by PTH and FGF23, which have opposite effects
on its activation in the kidney. 25D deficiency induces
an increase in PTH. Lower levels 25D are associated
with mortality in observational studies [12-14].
We hypothesize that disturbed mineral metabolism is
one explanation for the increased mortality risk associated
with decreased eGFR, and that FGF23, as a potentially
modifiable marker of phosphate load, is independently as-
sociated with mortality risk in an elderly community de-
rived population.
The primary aim of the present investigation is to
study the relationship between FGF23 and mortality,
in relation to the other parameters of mineral metab-
olism. The secondary aim is to study the relationship
between FGF23 and CVD related mortality. We will




The multicenter prospective Osteoporotic Fractures in
Men (MrOS) study which included older men in Sweden,
Hong Kong, and the United States aimed at examine
aspects of male osteoporosis and healthy ageing. We
used the participants in MrOS Sweden for this study.
Participants (men aged 69–81 years) were randomly
selected from national population register and invited
by letter. 45% of those contacted participated (n =
3014), constituting three sub cohorts in three cities:
Malmoe (n = 1005), Gothenburg (n = 1010) and Uppsala
(n = 999). Eligibility for study participation required the
ability to walk unassisted, to provide self-reported
data, and to understand and sign an informed consent.
The ethics committees at the Universities of Gothenburg
(approval number Gbg M 014–01), Malmoe (LU-693-00),
and Uppsala (Ups 01–057) approved of the study, which
were done in accordance with the declaration of Helsinki.
Assessment of parameters of mineral metabolism
Serum samples were collected after at least 10 hours of
fasting and stored at −80°C. Serum intact FGF23 was ana-
lyzed with a two-site monoclonal antibody based ELISA
(Kainos Laboratories International; Tokyo, Japan). The
assay has a lower limit of detection of 3 ng/L. Intra-assay
coefficient of variation was less than 5% and inter-assay
coefficient of variation was 6%. Levels of FGF23 wereavailable for 97% of the participants in the Gothenburg
cohort, 94% in the Malmoe cohort, and 91% in the
Uppsala cohort. Levels between 0 and 3 (N = 18) was
given the value 1.5 ng/L, and levels above 800 (N = 2) were
given the value 800 ng/L.
Intact PTH was measured by a second generation
immunometric assay, Immulite 2000, (Los Angeles, USA).
Serum PTH and FGF23 had right skewed distributions
and were log(10)-transformed to approximate normality.
When analyzed as a continuous variable they were fur-
ther z-transformed to allow reporting the results/(1-
standard deviation (SD)) change. 25D levels were mea-
sured by Nichols Advantage automated assay system
(San Juan Capistrano, CA, USA).
Assessment of mortality
Mortality data were collected from the population statis-
tics at Statistics Sweden. Follow-up time was recorded as
the period between baseline visit (in 2001–2004) and
date of death or mortality data collection (March 1,
2008). Cause of death data were collected from the
Swedish Cause of Death Register, held by the National
Board of Health and Welfare in Sweden, in which all
deaths in Sweden are registered with International Clas-
sification of Diseases (ICD) codes based on the informa-
tion from death certificates. The data were collected
from this register from the study start until the last up-
date of the register December 31, 2005 and from evalu-
ation of copies of death certificates for deaths occurring
after this date up to 2008. Based on the information
from the register or death certificates, the underlying
death cause was determined for each participant and
CVD death was defined by ICD-10 codes I00 to I99.
Assessment of covariates
A standardised questionnaire was used to gather informa-
tion about smoking and self-reported medical diagnoses
(hypertension, diabetes, cancer, myocardial infarction,
angina pectoris, and stroke). Prevalent CVD was defined
as a history of myocardial infarction, angina pectoris or
stroke. Hypertension was defined as self-reported anti-
hypertensive treatment for diagnosed hypertension or a sys-
tolic blood pressure above 140 mmHg measured once on
inclusion (supine blood pressure, measured after 10 minutes
rest). Body mass index (BMI) was calculated as weight/
height2 (kg/m2).
Phosphate, calcium and albumin were analyzed at
respective hospitals department for clinical chemistry
using standard methods. We report calcium and albumin
as separate variables. Estimated glomerular filtration rate
(eGFR) in ml/min/1.73 m2 was calculated from serum
cystatin C (Cystatin C Immunoparticles, Dako A/S,
Glostrup, Denmark) according to the formula 79.901*
(Cyst C [mg/L])-1.4389 [15].
Westerberg et al. BMC Nephrology 2013, 14:85 Page 3 of 10
http://www.biomedcentral.com/1471-2369/14/85Statistical analysis
The baseline variables are presented as mean ± SD for
normally distributed variables and as median (interquar-
tile range (IQR) 25th, 75th percentiles) for non-normally
distributed variables for the whole cohort and in quar-
tiles of FGF23. Mortality rates are reported as deaths per
1000-person-years.
Spearman correlation coefficients were calculated to
describe univariate correlations between FGF23, BMI,
eGFR, calcium, phosphate, PTH, and 25D.
Kaplan Meier curves were created for quartiles of
FGF23 showing proportion surviving all-cause death and
CVD related death. Differences between quartiles were
examined with Log rank test.
Cox proportional hazards regression was used to study
the association between mortality (all-cause and CVD-
cause) and FGF23, in quartiles and as a continuous vari-
able after adjustment for confounders. Associations be-
tween mortality and log (10)PTH and 25D were also
analyzed. Proportional hazard assumptions were con-
firmed by inspecting Schoenfeld residuals and linearity
assumptions by inspecting Martingales residuals.
The models were adjusted for potential confounders,
phosphate, calcium, albumin, PTH, 25D, eGFR and BMI,
as well as smoking, prevalent diabetes mellitus, hyper-
tension, cancer and prevalent CVD (coronary artery dis-
ease or stroke).Table 1 Characteristics and biochemical parameters of the wh
N = 2838 All Q
N = 2838 N =
FGF23 Range (pg/ml) 1.5-800 1.5-
FGF23 median (IQR)(pg/ml) 43.5 (32.4-57.5) 25.3 (1
Age (years) 75.5 ± 3.2 75.5
Weight (kg) 80.6 ± 12.1 77.8
BMI (kg/m2) 26.4 ± 3.6 25.6
Smoking (%) 8
Diabetes (%) 9
Hypertension (%) 36 3
Prevalent CVD 19 1
eGFR (ml/min/1.73 m2) 72.0 ± 20 80.2
PTH median IQR (pmol/L) 4.3 (3.0 - 5.8) 3.8 (2.
Pi (mmol/L) 1.07 ± 0.16 1.08
Ca (mmol/L) 2.36 ± 0.16 2.39
Albumin (g/L) 43.1 ± 3.6 43.4
25OHvitD (nmol/L) 69.8 ± 23.6 70.6
Mortality rate/1000 py (95%CI) 27.7 (24.9 - 30.7) 26.3 (20
Cardiovascular deaths/1000 py (95%CI) 10.3 (8.5 - 12.0) 7.1 (4
Descriptive statistics of the whole cohort and quartiles. IQR means interquartile ran
means body mass index and is calculated as weight in kg/(length in m) 2. CVD is ca
differ from Q1, analysed by ANOVA for continuous normally distributed variables anAge was included as a covariate in the first model.
eGFR and phosphate were included in the second
model, as they were judged the most relevant con-
founders based on biological plausibility as both eGFR
and phosphate potentially affects FGF23 and mortality
risk but are not in the causal pathway. In the third
model all available covariates, including 25D, log(10)
PTH and log(10)FGF23, where appropriate, and preva-
lent disorders, as well as BMI, were included to test if
the association in model 2 changed substantially. All
analyses were stratified for site. BMI and albumin were
included as confounders since both are strong predic-
tors for mortality and associated with parameters of
mineral metabolism. As the GFR is an essential factor
for all parameters of mineral metabolism we analyzed
the sub-cohorts with eGFR above or below 60 ml/min/
1.73 m2. We also analyzed those with, and without,
prevalent CVD separately.
P < 0.05 was considered statistically significant. Statis-
tical analyses were performed using Statistica Windows
(version 10.0 StatSoft, Chicago, IL).
Results
The characteristics of the whole cohort and quartiles
based on serum FGF23 level are presented in Table 1.
The mean (± SD) age was 75.5 ± 3.2 years and the eGFR
was 72.0 ± 20 μmol/L, the median (IQR) for FGF23 wasole cohort and Quartiles: Q1 to Q4 of FGF23
1 Q2 Q3 Q4
709 N = 710 N = 709 N = 710
32.2 32.4-43.4 43.5-57.4 57.5-800
9.2-28.8) 37.9 (35.3-40.4) 49.6 (46.5-53.0) 69.9 (62.7-85.5)
± 3.1 75.3 ± 3.2 75.5 ± 3.2 75.6 ± 3.2
± 11.3 80.7 ± 12.3* 81.1 ± 11.5* 82.9 ± 12.7*
± 3.4 26.4 ± 3.6* 26.5 ± 3.3* 27.0 ± 3.8*
9 8 8 8
7 10* 10* 10*
0 33 36* 45*
4 19* 19* 24*
± 18 75.2 ± 18* 71.1 ± 17* 61.5 ± 21*
7 - 5.1) 4.2* (3.0 - 5.8) 4.3* (3.0 - 5.8) 4.7* (3.2 - 6.4)
± 0.16 1.06 ± 0.17* 1.07 ± 0.16 1.08 ± 0.16
± 0.17 2.33 ± 0.16* 2.34 ± 0.14* 2.36 ± 0.15
± 3.7 43.5 ± 3.6 42.9 ± 3.6* 42.8 ± 3.5*
± 23.1 67.9 ± 23.3* 68.5 ± 22.4 72.2 ± 25.3
.8 - 31.8) 26.1 (20.6 - 31.7) 24.7 (19.2 - 30.1) 34.0 (27.9 - 41.0)
.3- 9.9) 12.2 (8.4- 15.9) 8.4 (5.2 - 11.6) 13.6 (9.5 - 17.8)
ge and is expressed as border for lowest quartile to highest quartile. BMI
rdiovascular disease, including coronary artery disease and stroke. * means
d by Kruskall-Wallis test for the others. P < 0.05 was considered significant.
Table 2 Spearman correlation coefficients between parameters of mineral metabolism and BMI
(N = 2838) BMI eGFR Albumin Calcium Phosphate 25D Log PTH
LogFGF23 0.12 * −0.35 * −0.06 * −0.06 * 0.001 N.S. 0.03 N.S. 0.19 *
LogPTH 0.03 N.S. −0.22 * 0.09 * −0.36 * −0.13 * −0.19 *
25D −0.12 * −0.006 N.S. 0.02 N.S. 0.13 * 0.04 *
Phosphate −0.05 * −0.05 * 0.11 * 0.15 *
Calcium 0.02 N.S. 0.05 * 0.17 *
Albumin −0.01 N.S. 0.07 *
eGFR −0.09 *
BMI is body mass index, eGFR is estimated glomerular filtration rate, 25D is 25 hydroxy vitamin D, * means significant correlation between parameters (P < 0.05).
N.S means non-significant.
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27.7 (24.9 - 30.7)/1000 py and the CVD related mortality
rate was 10.3 (8.5 - 12.0)/1000 py. With increasing quar-
tile of FGF23 eGFR decreased, PTH increased and
prevalence's of CVD and hypertension increased.Figure 1 LogFGF23, LogPTH, phosphate and 25 D in relation to eGFR
(N = 848), 75- < 90 (N = 740) and 90- (N = 487). 46 subjects excluded due
65 pg/ml for PTH and 75 and 50 nmol/L for 25 hydroxyl vitamin D (25D). T
multiply by 3.125 and 25D to ng/ml multiply by 0.4.Univariate correlations between parameters are presented
in Table 2. FGF23 correlated with decreasing eGFR and, to
some extent, calcium and PTH, but not with phosphate.
The parameters of mineral metabolism are depicted in
relation to eGFR in Figure 1. As eGFR decrease, FGF23<30 (N = 43), 30- < 45 (N = 181), 45- < 60 (N = 539), 60- < 75
to missing values. Reference lines indicate 50 pg/ml for FGF23,
o convert PTH to pmol/L multiply by 0.11, phosphate to mg/dL
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crease in FGF23 before PTH, as more than 25% of par-
ticipants with eGFR between 75 and 90 ml/min/1.73 m2
had FGF 23 levels above 50 ng/L, while over 75% had
PTH levels below 65 ng/L until eGFR was below 30 ml/
min/1.73 m2. Phosphate did not increase until eGFR was
below 30 ml/min/1.73 m2. There was no correlation be-
tween 25D levels and eGFR and the majority of partici-
pants had levels between 50 and 75 nmol/L.
Kaplan-Meier curves for quartiles of FGF23 and all-cause
mortality (Figure 2a) and CVD related mortality are shown
(Figure 2b). The cumulative proportion surviving was lower
in quartile 4 (FGF23 > 57.5 ng/L) (P < 0.05). The cumulative
proportion surviving CVD death was highest in quartile 1
and lowest in quartile 4 (P < 0.05). The proportion surviving
in quartiles 2 and 3 are intermediate, but their lines crossQ1       721 714 695
Q2       721 712 698
Q3       721 707 696
Q4       720 701 688






















































Q2   P<0.05
Q3    N.S.
Q4    P<0.05
Figure 2 Kaplan-Meier curves of proportional survival due to all-caus
P means probability for non difference to Q1 examined by Log-rank test.after about 3.5 years and the difference between quartile 1
and 3 becomes non-significant in the end.
In Cox proportional-hazard regression models analyzing
all-cause mortality (Table 3) for quartiles of FGF23, and for
log(10)FGF23, as a continuous variable there were no asso-
ciation after adjustment for eGFR and phosphate (only
eGFR contributed to the decrease in HR). The association
between log(10)PTH and all cause mortality in the un-
adjusted model waned after inclusion of eGFR. 25D was
significantly associated with all-cause mortality with a re-
duction in risk of 10% (95% CI 5-10%)/10 nmol/L increase
in 25D levels. Serum phosphate was not associated with
mortality, HR (95% CI) were 1.75 (0.93 - 3.30)/mmol/L in-
crease when adjusted for age.
Analysing all factors in stepwise Cox regression re-




g in Quartiles of FGF23. 
rtality.
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e (2a) and cardiovascular (2b) death for quartiles of FGF23.
Table 3 Description of sub-cohorts with eGFR above and below 60 ml/min/1.73 m2
N = 2838 eGFR ≥60 ml/min/1.73 m2 eGFR <60 ml/min/1.73 m2
N = 2075 N = 763
FGF23 Range (pg/ml) 1.5 - 800 3.5 - 800
FGF23 median (IQR)(pg/ml) 40.3 (30–52) 54.1 (40–70)
Age (years) 75.1 ± 3.2 76.4 ± 2.9
BMI (kg/m2) 26.2 ± 3.5 27.0 ± 3.7
Smoking (%) 138 (7%) 96 (12%)
Diabetes (%) 174 (8%) 90 (12%)
Hypertension (%) 661 (32%) 360 (47%)
Prevalent MI 12% 20%
Prevalent stroke 5% 9%
eGFR (ml/min/1.73 m2) 78 (70–89) 50 (43–55)
PTH median IQR (pmol/L) 4.1 (2.8 - 5.5) 4.9 (3.4 - 6.9)
Pi (mmol/L) 1.07 ± 0.16 1.09 ± 0.18
Ca (mmol/L) 2.36 ± 0.15 2.36 ± 0.17
Albumin (g/L) 43.3 ± 3.3 42.8 ± 4.2
25OHvitD (nmol/L) 69.9 ± 23 69.7 ± 24
Mortality rate/1000 py (95%CI) 219/9458.4 py 134/3309.1
23.2 (20.1 - 26.3) 40.5 (33.7 - 47.3)
Cardiovascular deaths/1000 py (95%CI) 73/9458.4 py 59/3309.1
7.7 (5.9 - 9.5) 17.8 (13.3 - 22.3)
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associated with all-cause mortality.
For CVD related death (Table 3) FGF23 was associated
with increased HR between quartiles 1 and 2, and between
1 and 4. When adjusted for eGFR and phosphate the asso-
ciation became non-significant (P = 0.06 for Q1 vs. Q2),
and when adjusted for the other parameters of mineral
metabolism and prevalent co morbidities it became even
weaker. When analyzed as a continuous variable the HR
(95%) for CVD death was 26% (−1 to 59%) higher/(1-SD)
increase in log(10)FGF23 in the multivariable model. The
association between PTH and cardiovascular mortality did
not remain when adjusted for eGFR and phosphate, and
the HR (95%) for CVD related death was −6% (−14 to
2%)/10 nmol/L increase in 25D.
The sub-cohort with eGFR below 60 ml/min/1.73 m2
(N = 763, 26.9%) compared to the sub cohort with
eGFR ≥ 60 ml/min/1.73 m2 had a mortality rate of 40.0
versus 23.1/1000 person-years (py), CVD mortality of
17.8 versus 7.7/1000 py, serum FGF23 of 54.1 (39.8 -
69.9) versus 40.3 (30.3 - 52.3) ng/L (Table 4).
The association between FGF23, PTH and 25D and
prevalent CVD and HR for CVD mortality in those with
eGFR above 60 ml/min/1.73 m2 (N = 2075, 218 deaths,
73 of CVD) are shown in Table 5. The HR (95% CI) for
CVD mortality was 55% (13–111%)/(1-SD) increase in
log(10)FGF23 in the multiadjusted model. PTH was notassociated with increased risk for CVD death. In partici-
pants without prevalent CVD (N= 2324, 252 deaths, 75 of
CVD) the HR (95% CI) for CVD death was 1.28 (0.95 -
1.56)/(1- SD) increase in log(10)FGF23.
Discussion
In this observational study of randomly selected elderly
men the FGF23 level on inclusion was not associated with
increased HR for mortality of all-cause. The HR (95% CI)
for death due to CVD was 1.26 (0.99-1.59)/(1-SD) increase
in log(10)FGF23 in the whole cohort, 1.55 (1.13 - 2.11) in
those without CKD (eGFR > 60 ml/min/1.73 m2, and 1.28
(0.95-1.72) in those without known CVD on inclusion.
Several studies have demonstrated an independent as-
sociation between FGF23 and mortality or cardiovascu-
lar events in CKD populations, but the association
between FGF23 and mortality in non-CKD populations
is not fully elucidated.
In a nested case–control study of incident haemodialy-
sis patients Gutierrez et al. demonstrated an odds ratio
(OR, 95% CI) of 5.7 (2.6 - 12.6) for death during first
year on dialysis for the highest quartile of carboxy-
terminal (C-)FGF23 (> 4010 RU/ml) compared to the
lowest(<1090 RU/ml) [16].
In a study by Isakova et al. of 3879 CKD 2–4 patients
from the Chronic Renal Insufficiency Cohort (CRIC)
followed for in median 3.5 years there were 266 deaths.
Table 4 Cox regression for association between mortality of all-cause and parameters of mineral metabolism
Factors Model 1 Model 2 Model 3
All cause mortality HR (95%CI) FGF23 age age, eGFR, phosphate age, BMI, eGFR, albumin, calcium, phosphate,
(PTH, FGF23 or 25D as appropriate), smoking, diabetes,
hypertension, prevalent cancer, prevalent CVD
Q1 ref ref ref
Q2 1.03 0.96 0.86
(0.75 - 1.40) (0.72 - 1.36) (0.60 - 1.25)
Q3 0.93 0.85 0.82
(0.67 - 1.29) (0.61 - 1.38) (0.58 - 1.16)
Q4 1.27 0.99 1.13
(0.94 - 1.73) (0.71 - 1.38) (0.80 - 1.59)
Log10FGF23/(1-SD) 1.09 1.01 1.02
0.97-1.22 0.89-1.14 0.89-1.17
Log PTH/(1-SD) 1.16 * 1.09 1.04
(1.03 - 1.30) (0.97 - 1.22) (0.92 - 1.18)
25D/10 nmol/L 0.90 ** 0.90 ** 0.91 **
(0.85 - 0.95) (0.85 - 0.95) (0.87 - 0.97)
CVD mortality HR (95%CI)
Q1 ref ref ref
Q2 1.76 * 1.66 1.67
(1.04 - 2.96) (0.98 - 2.83) (0.97 - 2.88)
Q3 1.15 1.00 0.80
(0.64 - 2.07) (0.55 - 1.82) (0.42 - 1.51)
Q4 1.86 * 1.30 1.37
(1.09 - 3.17) (0.73 - 2.32) (0.74 - 2.51)
Log10FGF23/(1-SD) 1.43 ** 1.26* 1.26
(1.18 - 1.73) (1.01 - 1.56) (0.99 - 1.59)
Log10PTH/(1-SD) 1.26 * 1.13 1.02
(1.04 - 1.52) (0.94 - 1.37) (0.84 - 1.23)
25D/10 nmol/L 0.92 * 0.91 * 0.94
(0.84 - 1.00) (0.84 - 0.99) (0.86 - 1.02)
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30–70%) increase in death/unit increase in logFGF23
[6]. Kendrick et al. examined 1099 CKD 4–5 patients
and found an association between higher FGF23 and
mortality risk [17]. Seiler et al. found in a cohort of
CKD patients (N = 149, eGFR = 36 ± 23 ml/min/1.73 m2)
that baseline FGF23 predicted future cardiovascular
complications [18].
There are also a few studies of FGF23 and mortality in
non-CKD populations. Parker et al. described in a co-
hort of 833 persons, with prevalent stable coronary dis-
ease, a HR (95% CI) for death of 40% (22–60%)/doubling
of FGF23. The majority of deaths were due to cardiovas-
cular disease and there was an association between
FGF23 and heart failure and stroke, but not with myo-
cardial infarction [11].Taylor et al. made a nested case–control study from a
large cohort of healthy males (age 63.6 ± 8.6 years, cre-
atinine 1.0 ± 0.2 mg/dL). During 10 years follow-up 422
developed myocardial infarction or died of coronary
heart disease. Cases did not differ from the 837 controls
concerning C-FGF23 58.6 (47.8 - 73.7) vs. 57.1 (47.4 -
72.2) RU/ml. or PTH, while 25D was significantly lower
in cases [19].
Ix et al. reported of the association between C-FGF23
and death, heart failure and CVD in the general popula-
tion. They followed 3017 persons 65 years or older (mean
age 78 ± 5 years), without active cancer treatment, for in
median 10.5 years and 1730 deaths occurred. They found
a HR (95% CI) for all cause death of 25% (14–36%)/doub-
ling of C-FGF23, incident heart failure of 41% (23–61%)
and of incident CVD of 12% (−2%-29%) [20].






BMI, eGFR, albumin, calcium, phosphate,
(PTH, FGF23 or 25D as appropriate), smoking, diabetes,
hypertension, prevalent cancer, prevalent CVD
Mortality HR (95% CI)
Log10FGF23/(1 - SD) 1.02 1.02 1.02
(0.88 - 1.19) (0.87 - 1.18) (0.86 - 1.20)
Log10PTH/(1 - SD) 1.08 1.11 1.05
(0.93 - 1.28) (0.94 - 1.31) (0.88 - 1.24)
25D/10 nmol/L 0.88 0.86 0.83
(0.78 - 0.98) (0.78 - 95) (0.70 - 0.96)
Cardiovascular mortality HR (95% CI)
Log10FGF23/(1-SD) 1.45* 1.44* 1.55*
(1.11 - 1.89) (1.09 - 1.89) (1.13 - 2.11)
Log10PTH/(1-SD) 1.16 1.14 0.98
(0.87 - 1.53) (0.87 - 1.52) (0.74 - 1.30)
25D/10 nmol/L 0.88* 0.88* 0.89
(0.77 - 0.99) (0.77 - 0.99) (0.78 - 1.01)
Cox Hazards regression models of CVD-related death and parameters of mineral metabolism in the sub-cohort without prevalent cardiovascular disease
No prevalent CVD (N = 2324)
CVD mortality
HR (95% CI)
Log10FGF23/(1-SD) 1.37* 1.29 1.28
(1.06 - 1.77) (0.98 - 1.71) (0.95 - 1.72)
Log10PTH/(1-SD) 1.16 1.11 1.10
(0.89 - 1.52) (0.85 - 1.44) (0.85 - 1.43)
25D/10 nmol/L 0.92 0.92 0.94
(0.82 - 1.03) (0.82 - 1.03) (0.84 - 1.05)
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http://www.biomedcentral.com/1471-2369/14/85A recent report of a community derived cohort of eld-
erly men describes an association between intact FGF23
and all-cause and cardiovascular mortality. The effect is
mainly driven by the strong increase in risk for CVD death
among the quintile with highest FGF23 (> 60 ng/L), and
among individuals with decreased renal function. That
study also indicate that a very low FGF23 is associated
with the lowest risk for CVD death [21].
Our study, on the other hand, does not demonstrate
an association between FGF23 and all-cause death. We
study a homogenous group of randomly selected volun-
tary Swedish males, avoiding bias due to gender or eth-
nicity, but probably introducing bias to more health
interested and active persons. The mortality rate due to
CVD was only 37% of total mortality rate, which may
explain the negative result between FGF23 and all-cause
mortality. In crude analysis there is an association be-
tween FGF23 and CVD mortality, but the relationship is
not linear when analyzed in quartiles and the increased
risk in quartile 4 (FGF23 > 57 ng/L) vanishes afteradjustment for eGFR. Though, renal dysfunction ex-
plains most, or all, of the association between FGF23
and CVD mortality. Analyzed as a continuous variable
there is a 25% increase in HR for CVD death/(1 - SD)
increase in Log10FGF23, but the formal significance is
borderline (P = 0.06). The association in the sub cohort
with eGFR above 60 ml/min/1.73 m2 remained signifi-
cant after adjustment, Death due to CVD in this study
includes heart failure and stroke, but also myocardial in-
farction, pulmonary embolism and arrhythmias for
which the association may be weaker or absent, in ac-
cordance with the other studies. One explanation for the
divergent findings may be that eGFR is associated with
increased mortality and with increased FGF23. In CKD
populations FGF23 levels may indicate increased risk
due to duration of decreased renal function, phosphate
load or specific renal injury, while in a rather healthy
population where decreased GFR mostly is due to preva-
lent CVD FGF23 may not add much information about
mortality risk.
Westerberg et al. BMC Nephrology 2013, 14:85 Page 9 of 10
http://www.biomedcentral.com/1471-2369/14/85When excluding those with decreased eGFR FGF23
still is associated with a modest increase in HR for CVD
death. The explanation may be that lower FGF23 signals
better renal function, lower BMI and maybe lower intake
of phosphate creating a low risk profile for CVD not
fully adjusted for in the models.
Phosphate was not associated with mortality or even
with FGF23 in this study. That may be explained by
the generally good renal function. Higher phosphate
would lead to higher FGF23 but as long as renal func-
tion is able to increase the fractional excretion of phos-
phate in response to FGF23, and PTH, normophospahtemia
will prevail.
In several earlier studies FGF23 was analyzed with
an assay detecting intact and carboxy-terminal FGF23
(C-FGF23), which has been shown to correlate strongly
with intact FGF23 independently of GFR. We measured
intact FGF23 in serum since at the time of analysis there
was concern for accumulation of C-terminal fragments as
renal function declined. Recent reports suggest instability
of the intact FGF23 molecule in vitro and rather under-
estimation of circulating FGF23, but immediate centrifu-
gation and freezing should minimize this source of
attenuation of effect. We do not believe the choice of assay
caused the lack of association with mortality in our study,
but it cannot be excluded, and direct comparisons of dif-
ferent FGF23 assays will be necessary in the future.
We also report the lack of an association between
PTH and HR for all-cause and CVD death after adjust-
ment for eGFR.
Higher 25D levels was associated with lower HR for
death of all-cause even after adjustments, which has
been described in detail in this cohort earlier [22].
Strengths of this study are that it describes a large
community-derived cohort with a relatively large num-
ber of events and complete data of survival. The popula-
tion is homogenous concerning gender and ethnicity.
Renal function is evaluated with a cystatin C based for-
mula. The Swedish official cause of death register is
comprehensive and reliable
There are also several limitations. It is not possible to
generalize the results to females, other age-groups or
ethnicities. Even if the vital status of the subjects were
certain, we used the cause of death code from the Na-
tional cause of death register and they were not adjudi-
cated by clinicians. Differentiating between CVD related
causes of death would have been informative, since the
putative mechanism would explain an association with
heart failure rather than acute coronary syndromes. Data
about prevalent disease were provided by the subjects
and may have caused misclassifications. FGF23 was mea-
sured as single measurements. These limitations may
lead to an underestimation of the association between
FGF23 and outcome. 1,25 dihydroxy vitamin D levels,lipid levels and other known CVD risk markers were not
available in this study. We also lacked data of phosphate
intake and renal phosphate excretion.
Conclusion
In the general population there is no association be-
tween FGF23 levels and death of all-cause independent
of eGFR. There is a possible association between higher
FGF23 and CVD deaths in individuals with normal renal
function. Higher FGF23 is associated with CVD death
due to decreased renal function, while the lowest FGF23
levels may indicate a low risk profile for CVD disease.
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